International journal of women's health · 2026
Synergistic Efficacy of Calcitriol Combined with Denosumab versus Calcitriol Alone in Postmenopausal Osteoporosis: A Retrospective Cohort Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Xueyuan, Hu Ming, Shen Yi
Аннотация
OBJECTIVE: To evaluate the efficacy and safety of calcitriol combined with denosumab versus calcitriol alone in postmenopausal osteoporosis (PMO).
METHODS: In this retrospective cohort study, 306 postmenopausal women with PMO were divided into two groups: an intervention group (n = 144) receiving calcitriol, denosumab, and calcium/vitamin D3, and a control group (n = 162) receiving calcitriol and calcium/vitamin D3 only, over 12 months. Outcomes included bone mineral density (BMD), bone turnover markers, calcium-phosphate homeostasis, patient-reported outcomes (VAS, ODI, BI), and adverse events.
RESULTS: The intervention cohort demonstrated more pronounced enhancements in BMD measured at the lumbar spine, femoral neck, and total hip (all P < 0.05). Additionally, there was a more marked reduction in bone turnover markers, namely β-C-terminal telopeptide of type I collagen (β-CTX), Tartrate-resistant acid phosphatase 5b (TRACP-5b), Procollagen type I N-terminal propeptide (P1NP), and Bone Gla Protein (BGP) (P < 0.05). Superior regulation of calcium-phosphate homeostasis-reflected by Parathyroid Hormone (PTH) and 25-hydroxyvitamin D [25(OH)D] levels-was also observed in this group (P < 0.05). Patient-reported outcomes (VAS, ODI, BI) also improved more markedly (P < 0.05). The incidence of adverse events was low and comparable between groups, with no serious events reported.
CONCLUSION: Calcitriol combined with denosumab synergistically enhances BMD, suppresses bone turnover, improves functional outcomes, and maintains a favorable safety profile in PMO, representing a promising therapeutic strategy.
METHODS: In this retrospective cohort study, 306 postmenopausal women with PMO were divided into two groups: an intervention group (n = 144) receiving calcitriol, denosumab, and calcium/vitamin D3, and a control group (n = 162) receiving calcitriol and calcium/vitamin D3 only, over 12 months. Outcomes included bone mineral density (BMD), bone turnover markers, calcium-phosphate homeostasis, patient-reported outcomes (VAS, ODI, BI), and adverse events.
RESULTS: The intervention cohort demonstrated more pronounced enhancements in BMD measured at the lumbar spine, femoral neck, and total hip (all P < 0.05). Additionally, there was a more marked reduction in bone turnover markers, namely β-C-terminal telopeptide of type I collagen (β-CTX), Tartrate-resistant acid phosphatase 5b (TRACP-5b), Procollagen type I N-terminal propeptide (P1NP), and Bone Gla Protein (BGP) (P < 0.05). Superior regulation of calcium-phosphate homeostasis-reflected by Parathyroid Hormone (PTH) and 25-hydroxyvitamin D [25(OH)D] levels-was also observed in this group (P < 0.05). Patient-reported outcomes (VAS, ODI, BI) also improved more markedly (P < 0.05). The incidence of adverse events was low and comparable between groups, with no serious events reported.
CONCLUSION: Calcitriol combined with denosumab synergistically enhances BMD, suppresses bone turnover, improves functional outcomes, and maintains a favorable safety profile in PMO, representing a promising therapeutic strategy.